{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:40:15Z","timestamp":1791639615875,"version":"4.3.4"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Primary open-angle glaucoma (POAG) is a chronic progressive optic neuropathy often associated with increased intraocular pressure (IOP). Monitoring glaucoma progression velocity, for example, the rate of change in global indices such as mean deviation (MD), is a common way to determine whether functional deterioration has occurred. This systematic review aims to assess changes in glaucoma progression velocity in response to IOP-lowering therapy at an individual level. A systematic review was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. A comprehensive search of PubMed, Cochrane CENTRAL, and ClinicalTrials.gov from database inception through November 12, 2023, was conducted for randomized clinical trials involving patients with POAG, normal tension glaucoma, or progressive ocular hypertension who received IOP-lowering therapy with a target IOP reduction \u226520% from baseline. Included trials were required to report visual field progression velocity information for individual patients before and after intervention. One study was found to meet inclusion criteria and, therefore, synthesis of data and meta-analysis were unable to be performed. The study reports on 139 eyes of 109 patients from the Ocular Hypertension Treatment Study who reached a POAG endpoint. In these patients, the post-treatment rate of MD change (\u22120.27\u2009\u00b1\u20090.7 dB\/year) was significantly slower than the pre-treatment rate (\u22120.51\u2009\u00b1\u20090.8), P\u2009&lt;\u20090.01. In addition, the rate of MD change significantly correlated with mean IOP reduction (p\u2009&lt;\u20090.001). The singular study demonstrated that IOP-lowering therapy did variably slow glaucoma progression rate in that patient cohort. There is a need for more studies that focus on individual patients\u2019 responses to glaucoma treatment. Furthermore, this information should be used to classify the magnitude of patients\u2019 responsiveness to IOP reduction. Future studies should report pre- and post-intervention progression velocities.<\/jats:p>","DOI":"10.1371\/journal.pone.0324806","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T17:28:27Z","timestamp":1748539707000},"page":"e0324806","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Changes in individuals\u2019 glaucoma progression velocity after IOP-lowering therapy: A systematic review"],"prefix":"10.1371","volume":"20","author":[{"given":"Vihar","family":"Naik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran","family":"Ohri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5089-0345","authenticated-orcid":true,"given":"Elise","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Mwanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1043-2021","authenticated-orcid":true,"given":"David","family":"Fleischman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"pone.0324806.ref001","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-76700-0","volume-title":"The Glaucoma Book","author":"PN Schacknow","year":"2010"},{"issue":"18","key":"pone.0324806.ref002","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"RN Weinreb","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"pone.0324806.ref003","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0002-9394(03)00478-1","article-title":"Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma","volume":"136","author":"Collaborative Normal-Tension Glaucoma Study Group","year":"2003","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"pone.0324806.ref004","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/archophthalmol.2010.196","article-title":"Canadian Glaucoma Study: 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field change","volume":"128","author":"BC Chauhan","year":"2010","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"pone.0324806.ref005","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ophtha.2007.03.016","article-title":"Predictors of long-term progression in the early manifest glaucoma trial","volume":"114","author":"MC Leske","year":"2007","journal-title":"Ophthalmology"},{"issue":"4","key":"pone.0324806.ref006","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","article-title":"The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators","volume":"130","year":"2000","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"pone.0324806.ref007","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/bjo.2007.135012","article-title":"Practical recommendations for measuring rates of visual field change in glaucoma","volume":"92","author":"BC Chauhan","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"pone.0324806.ref008","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00055735-200304000-00006","article-title":"Collaborative normal tension glaucoma study","volume":"14","author":"DR Anderson","year":"2003","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"pone.0324806.ref009","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0161-6420(00)00518-2","article-title":"Natural history of normal-tension glaucoma","volume":"108","author":"Collaborative Normal-Tension Glaucoma Study Group","year":"2001","journal-title":"Ophthalmology"},{"key":"pone.0324806.ref010","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"MJ Page","year":"2021","journal-title":"BMJ"},{"issue":"6","key":"pone.0324806.ref011","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"MA Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"pone.0324806.ref012","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"JAC Sterne","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"pone.0324806.ref013","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1167\/iovs.11-8186","article-title":"Effect of treatment on the rate of visual field change in the ocular hypertension treatment study observation group","volume":"53","author":"CG De Moraes","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"pone.0324806.ref014","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/archopht.117.5.573","article-title":"The Ocular Hypertension Treatment Study: design and baseline description of the participants","volume":"117","author":"MO Gordon","year":"1999","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"pone.0324806.ref015","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/archopht.120.6.714","article-title":"The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma","volume":"120","author":"MO Gordon","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"pone.0324806.ref016","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/IJG.0000000000001285","article-title":"Effects of Brimonidine and Timolol on the Progression of Visual Field Defects in Open-angle Glaucoma: A Single-center Randomized Trial","volume":"28","author":"Y Yokoyama","year":"2019","journal-title":"J Glaucoma"},{"issue":"10","key":"pone.0324806.ref017","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.ophtha.2020.03.029","article-title":"Visual Field Outcomes from the Multicenter, Randomized Controlled Laser in Glaucoma and Ocular Hypertension Trial (LiGHT)","volume":"127","author":"DM Wright","year":"2020","journal-title":"Ophthalmology"},{"issue":"4","key":"pone.0324806.ref018","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s10384-010-0815-z","article-title":"Visual field loss in patients with normal-tension glaucoma under topical nipradilol or timolol: subgroup and subfield analyses of the nipradilol-timolol study","volume":"54","author":"M Araie","year":"2010","journal-title":"Jpn J Ophthalmol"},{"issue":"11","key":"pone.0324806.ref019","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0161-6420(01)00873-9","article-title":"Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery","volume":"108","author":"PR Lichter","year":"2001","journal-title":"Ophthalmology"},{"key":"pone.0324806.ref020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ajo.2022.09.011","article-title":"Two-Year Visual Field Outcomes of the Treatment of Advanced Glaucoma Study (TAGS)","volume":"246","author":"G Montesano","year":"2023","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"pone.0324806.ref021","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.ophtha.2020.02.034","article-title":"Visual Field Outcomes in the Tube Versus Trabeculectomy Study","volume":"127","author":"SS Swaminathan","year":"2020","journal-title":"Ophthalmology"},{"issue":"2","key":"pone.0324806.ref022","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ophtha.2008.08.051","article-title":"Visual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors","volume":"116","author":"DC Musch","year":"2009","journal-title":"Ophthalmology"},{"issue":"4","key":"pone.0324806.ref023","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0002-9394(98)00223-2","article-title":"Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group","volume":"126","year":"1998","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"pone.0324806.ref024","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.ophtha.2020.06.009","article-title":"Risk Factors for Visual Field Deterioration in the United Kingdom Glaucoma Treatment Study","volume":"127","author":"P Founti","year":"2020","journal-title":"Ophthalmology"},{"issue":"9975","key":"pone.0324806.ref025","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","article-title":"Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial","volume":"385","author":"DF Garway-Heath","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"pone.0324806.ref026","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.ophtha.2009.06.042","article-title":"Natural history of open-angle glaucoma","volume":"116","author":"A Heijl","year":"2009","journal-title":"Ophthalmology"},{"issue":"10","key":"pone.0324806.ref027","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/IJG.0000000000001342","article-title":"Making a correct diagnosis of glaucoma: data from the EMGT","volume":"28","author":"H \u00d6hnell","year":"2019","journal-title":"J Glaucoma"},{"key":"pone.0324806.ref028","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.10.001","article-title":"Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma","volume":"56","author":"CG De Moraes","year":"2017","journal-title":"Prog Retin Eye Res"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T17:28:35Z","timestamp":1748539715000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324806"}},"subtitle":[],"editor":[{"given":"Petros Cyrus","family":"Kayange","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0324806","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]}}}